Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Troxerutin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Acquisition
STADA becomes a major Consumer Healthcare player by acquiring 15 well-established GSK brands
Details : The transaction represents 15 brands including Venoruton, for venous treatment; Coldrex cold remedy; Cetebe vitamin C supplements; Mebucaine sore throat range and Tavegyl allergy brand.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 24, 2020
Lead Product(s) : Troxerutin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?